scholarly journals [18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Martina Sollini ◽  
Francesco Bartoli ◽  
Lara Cavinato ◽  
Francesca Ieva ◽  
Alessandra Ragni ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Distant Metastases ◽  
Tumor Burden ◽  
Similarity Analysis ◽  
Regional Lymph Nodes ◽  
Pet Ct ◽  
Oligometastatic Prostate Cancer ◽  
Radical Therapy ◽  
Definition Of

Abstract Background The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [18F]FMCH PET/CT radiomic analysis in patients with recurrent PCa after primary radical therapy. Specifically, we tested intra-patient lesions similarity in oligometastatic and plurimetastatic PCa, comparing the two most used definitions of oligometastatic disease. Methods PCa patients eligible for [18F]FMCH PET/CT presenting biochemical failure after first-line curative treatments were invited to participate in this prospective observational trial. PET/CT images of 92 patients were visually and quantitatively analyzed. Each patient was classified as oligometastatic or plurimetastatic according to the total number of detected lesions (up to 3 and up to 5 or > 3 and > 5, respectively). Univariate and intra-patient lesions' similarity analysis were performed. Results [18F]FMCH PET/CT identified 370 lesions, anatomically classified as regional lymph nodes and distant metastases. Thirty-eight and 54 patients were designed oligometastatic and plurimetastatic, respectively, using a 3-lesion threshold. The number of oligometastic scaled up to 60 patients (thus 32 plurimetastatic patients) with a 5-lesion threshold. Similarity analysis showed high lesions' heterogeneity. Grouping patients according to the number of metastases, patients with oligometastatic PCa defined with a 5-lesion threshold presented lesions heterogeneity comparable to plurimetastic patients. Lesions within patients having a limited tumor burden as defined by three lesions were characterized by less heterogeneity. Conclusions We found a comparable heterogeneity between patients with up to five lesions and plurimetastic patients, while patients with up to three lesions were less heterogeneous than plurimetastatic patients, featuring different cells phenotypes in the two groups. Our results supported the use of a 3-lesion threshold to define oligometastatic PCa.

scholarly journals Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting

2017 ◽  
Vol 9 (5) ◽  
pp. 307-318 ◽  
Author(s):  
Javier Puente ◽  
Enrique Grande ◽  
Ana Medina ◽  
Pablo Maroto ◽  
Nuria Lainez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Paradigm Shift ◽  
Distant Metastases ◽  
Tumor Burden ◽  
Potential Toxicity ◽  
Ablation Therapy ◽  
Androgen Ablation ◽  
Hormone Sensitive ◽  
Androgen Ablation Therapy

The increasing knowledge of prostate cancer is leading to many questions about its natural history and to reconsider conventional therapeutic strategies. Androgen ablation therapy has been the standard therapy in the advanced setting. Although docetaxel has demonstrated increased survival in patients with metastatic prostate cancer who had progressed to hormone treatments, due to its potential toxicity the role of chemotherapy has been relegated to patients who were symptomatic or who had high tumor burden. Several studies have assessed whether docetaxel could have a role in hormone-sensitive disease or even in earlier stages with no distant metastases. In the CHAARTED and STAMPEDE studies, docetaxel provides an unprecedented increase in overall survival (OS). This review summarizes the evidence behind the paradigm shift to strengthening docetaxel as a new standard of treatment that prolongs survival in earlier stages of prostate cancer.

Oligometastatic prostate cancer treatment

2021 ◽  
Author(s):  
Sabrina Rossetti ◽  
Marilena Di Napoli ◽  
Carmela Pisano ◽  
Sabrina C Cecere ◽  
Rosa Tambaro ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Imaging Techniques ◽  
Treatment Strategies ◽  
Ct Scanning ◽  
Tumor Burden ◽  
Prostate Cancer Treatment ◽  
Oligometastatic Disease ◽  
Pet Ct ◽  
Oligometastatic Prostate Cancer ◽  
Localized Disease

Oligometastatic prostate cancer is an intermediate state between localized disease and widespread metastasis. Its biological and clinical peculiarities are still to be elucidated. New imaging techniques contribute to the detection of patients with oligometastatic disease. PET/CT scanning with prostate-specific membrane antigen can improve the selection of men with true early, low-volume oligometastatic disease, who are candidates for metastasis-directed therapy. Clinical studies demonstrated that androgen deprivation therapy can be delayed in oligometastatic patients with a low tumor burden, although no survival benefit has been demonstrated at present. This article presents available evidence on the treatment strategies for oligometastatic prostate cancer.

scholarly journals Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 552
Author(s):  
Salam Awenat ◽  
Arnoldo Piccardo ◽  
Patricia Carvoeiras ◽  
Giovanni Signore ◽  
Luca Giovanella ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Diagnostic Accuracy ◽  
Metastatic Disease ◽  
Cancer Staging ◽  
Relevant Information ◽  
Cochrane Library ◽  
Number Of Patients ◽  
Pet Ct

Background: The use of prostate-specific membrane antigen (PSMA)-targeted agents for staging prostate cancer (PCa) patients using positron emission tomography/computed tomography (PET/CT) is increasing worldwide. We performed a systematic review on the role of 18F-PSMA-1007 PET/CT in PCa staging to provide evidence-based data in this setting. Methods: A comprehensive computer literature search of PubMed/MEDLINE and Cochrane Library databases for studies using 18F-PSMA-1007 PET/CT in PCa staging was performed until 31 December 2020. Eligible articles were selected and relevant information was extracted from the original articles by two authors independently. Results: Eight articles (369 patients) evaluating the role of 18F-PSMA-1007 PET/CT in PCa staging were selected. These studies were quite heterogeneous, but, overall, they demonstrated a good diagnostic accuracy of 18F-PSMA-1007 PET/CT in detecting PCa lesions at staging. Overall, higher primary PCa aggressiveness was associated with higher 18F-PSMA-1007 uptake. When compared with other radiological and scintigraphic imaging methods, 18F-PSMA-1007 PET/CT had superior sensitivity in detecting metastatic disease and the highest inter-reader agreement. 18F-PSMA-1007 PET/CT showed similar results in terms of diagnostic accuracy for PCa staging compared with PET/CT with other PSMA-targeted tracers. Dual imaging with multi-parametric magnetic resonance imaging and 18F-PSMA-1007 PET/CT may improve staging of primary PCa. Notably, 18F-PSMA-1007-PET/CT may detect metastatic disease in a significant number of patients with negative standard imaging. Conclusions: 18F-PSMA-1007 PET/CT demonstrated a good accuracy in PCa staging, with similar results compared with other PSMA-targeted radiopharmaceuticals. This method could substitute bone scintigraphy and conventional abdominal imaging for PCa staging. Prospective multicentric studies are needed to confirm these findings.

Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases

2013 ◽  
Vol 52 (8) ◽  
pp. 1622-1628 ◽  
Author(s):  
Ulrike Schick ◽  
Sandra Jorcano ◽  
Philippe Nouet ◽  
Michel Rouzaud ◽  
Hansjoerg Vees ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Distant Metastases ◽  
Androgen Deprivation ◽  
High Dose ◽  
Oligometastatic Prostate Cancer

Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer

2008 ◽  
Vol 113 (6) ◽  
pp. 895-904 ◽  
Author(s):  
E. Pelosi ◽  
V. Arena ◽  
A. Skanjeti ◽  
V. Pirro ◽  
A. Douroukas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Whole Body ◽  
Disease Detection ◽  
Biochemical Relapse ◽  
Radical Treatment ◽  
Choline Pet ◽  
Pet Ct

Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET/CT vs PET/MRI

2021 ◽  
Author(s):  
Feng-Yuan Liu ◽  
Ting-Wen Sheng ◽  
Jing-Ren Tseng ◽  
Kai-Jie Yu ◽  
Ke-Hong Tsui ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Local Recurrence ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Staging ◽  
Distant Metastases ◽  
Local Tumor ◽  
Pet Ct ◽  
Primary Tumor Detection

Objectives: To investigate whether PET/CT or PET/MRI is more appropriate for imaging prostate cancer, in terms of for primary tumor detection, local staging and recurrence, as well as lymph nodes and distant metastases. Methods: A systematic literature search was conducted on Embase, PubMed/MEDLINE, and the Cochrane Library database. Studies evaluating the diagnostic performance of PET/CT vs PET/MRI in prostate cancer patients were emphasized. Results: We reviewed 57 original research articles during the period 2016—2021: 14 articles regarding the radiotracer PSMA; 18 articles regarding the primary tumor detection, local tumor staging, managing local recurrence; 17 articles for managing lymph node metastases; and eight articles for managing bone and other distant metastases. PSMA PET could be complementary to mpMRI for primary prostate cancer localization and is particularly valuable for PI-RADS three lesions. PET/MRI is better than PET/CT in local tumor staging due to its specific benefit in predicting extracapsular extension in MRI-occult prostate cancer patients. PET/MRI is likely superior as compared with PET/CT in detecting local recurrence, and have slightly higher detection rates than PET/CT in lymph node recurrence. PET/CT and PET/MRI seem to have equivalent performance in detecting distant bony or visceral metastases. Conclusion: In conclusion, PET/MRI is suitable for local and regional disease, either primary staging or restaging whereas PET/CT is valuable for managing distant bony or visceral metastasis. Advances in knowledge: We reviewed the emerging applications of PET/MRI and PET/CT in clinical aspects. Readers will gain an objective overview on the strength and shortfalls of PET/MRI or PET/CT in the management of prostate cancer.

High-risk, recurrent and oligometastatic prostate cancer: recent developments on the role of radiation

2021 ◽  
Vol 33 (3) ◽  
pp. 238-243
Author(s):  
Jason K. Molitoris ◽  
Gregory S. Alexander ◽  
Osman Siddiqui ◽  
Justin Cohen ◽  
Mark V. Mishra ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Oligometastatic Prostate Cancer ◽  
Recent Developments
Sign in / Sign up

Export Citation Format

Share Document